$CRBU
Caribou Biosciences Inc Stock $crbu

$crbu Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000161985622000022 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q4
Revenue	$3.692M	$3.303M	$2.559M
YoY Change	44.28%	-16.95%	160.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.534M	$9.849M	$7.853M
YoY Change	8.67%	45.7%	88.19%
% of Gross Profit
Research & Development	$25.74M	$19.99M	$15.11M
YoY Change	70.31%	26.26%	25.67%
% of Gross Profit
Depreciation & Amortization	$506.0K	$450.0K	$273.0K
YoY Change	85.35%	73.08%	-59.5%
% of Gross Profit
Operating Expenses	$34.27M	$29.84M	$22.96M
YoY Change	49.23%	32.08%	41.8%
Operating Profit		-$26.54M	-$20.41M
YoY Change		42.55%	34.15%
Interest Expense	-$60.00K	$31.00K	$76.00K
YoY Change	-178.95%		4.11%
% of Operating Profit
Other Income/Expense, Net	$3.719M	-$110.0K	$2.247M
YoY Change	65.51%	-95.34%	1359.09%
Pretax Income	-$26.92M	-$26.65M	-$18.16M
YoY Change	48.25%	27.05%	20.6%
Income Tax	$70.00K	$0.00	$321.0K
% Of Pretax Income
Net Earnings	-$26.99M	-$26.65M	-$18.48M
YoY Change	46.05%	27.05%	25.68%
Net Earnings / Revenue	-731.01%	-806.75%	-722.12%
Basic Earnings Per Share		-$0.44
Diluted Earnings Per Share	-$0.44	-$0.44	-$305.5K
COMMON SHARES
Basic Shares Outstanding	61.00M shares	60.89M shares	60.19M
Diluted Shares Outstanding		60.89M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$247.7M	$293.4M	$240.6M
YoY Change	2.92%	-32.61%
Cash & Equivalents	$58.34M	$82.09M	$240.4M
Short-Term Investments	$189.3M	$211.3M	$226.0K
Other Short-Term Assets	$7.921M	$8.558M	$7.236M
YoY Change	9.47%	43.78%
Inventory
Prepaid Expenses
Receivables	$202.0K	$397.0K	$1.153M
Other Receivables	$7.000K	$3.000K	$555.0K
Total Short-Term Assets	$260.2M	$306.9M	$391.2M
YoY Change	-33.47%	-31.65%	1509.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.68M	$8.959M	$4.887M
YoY Change	118.5%	100.11%	39.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.698M	$7.759M	$7.626M
YoY Change	0.94%	1.74%	0.0%
Other Assets	$1.538M	$1.336M	$975.0K
YoY Change	57.74%	64.94%	59.31%
Total Long-Term Assets	$113.5M	$91.90M	$51.16M
YoY Change	121.87%	611.69%	335.81%
TOTAL ASSETS
Total Short-Term Assets	$260.2M	$306.9M	$391.2M
Total Long-Term Assets	$113.5M	$91.90M	$51.16M
Total Assets	$373.8M	$398.8M	$442.4M
YoY Change	-15.51%	-13.67%	1127.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.146M	$1.228M	$3.990M
YoY Change	-71.28%	-64.73%	53.4%
Accrued Expenses	$16.08M	$14.64M	$13.14M
YoY Change	22.4%	5.08%	46.39%
Deferred Revenue	$9.937M	$12.04M	$8.703M
YoY Change	14.18%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$28.13M	$28.81M	$25.83M
YoY Change	8.9%	10.15%	108.48%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$44.39M	$45.42M	$28.23M
YoY Change	57.25%	45.36%
Total Long-Term Liabilities	$44.39M	$45.42M	$28.23M
YoY Change	57.25%	45.36%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.13M	$28.81M	$25.83M
Total Long-Term Liabilities	$44.39M	$45.42M	$28.23M
Total Liabilities	$72.89M	$74.71M	$54.53M
YoY Change	33.67%	29.8%	200.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$197.2M	-$170.2M	-$97.79M
YoY Change	101.65%	114.63%	216.78%
Common Stock	$6.000K	$6.000K	$6.000K
YoY Change	0.0%	0.0%	500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$300.9M	$324.1M	$387.8M
YoY Change
Total Liabilities & Shareholders Equity	$373.8M	$398.8M	$442.4M
YoY Change	-15.51%	-13.67%	1127.2%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q4
OPERATING ACTIVITIES
Net Income	-$26.99M	-$26.65M	-$18.48M
YoY Change	46.05%	27.05%	25.68%
Depreciation, Depletion And Amortization	$506.0K	$450.0K	$273.0K
YoY Change	85.35%	73.08%	-59.5%
Cash From Operating Activities	-$25.04M	-$22.38M	-$21.39M
YoY Change	17.09%	49.5%	-10.78%
INVESTING ACTIVITIES
Capital Expenditures	$1.757M	-$1.354M	-$685.0K
YoY Change	-356.5%	45.59%	628.72%
Acquisitions
YoY Change
Other Investing Activities	$2.927M	-$6.985M	-$173.3M
YoY Change	-101.69%	598.5%	30677.26%
Cash From Investing Activities	$1.170M	-$8.339M	-$174.0M
YoY Change	-100.67%	332.07%	26378.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	127.0K	654.0K	460.0K
YoY Change	-72.39%	-99.8%	-73.94%
NET CHANGE
Cash From Operating Activities	-25.04M	-22.38M	-21.39M
Cash From Investing Activities	1.170M	-8.339M	-174.0M
Cash From Financing Activities	127.0K	654.0K	460.0K
Net Change In Cash	-23.75M	-30.06M	-194.9M
YoY Change	-87.82%	-109.83%	752.39%
FREE CASH FLOW
Cash From Operating Activities	-$25.04M	-$22.38M	-$21.39M
Capital Expenditures	$1.757M	-$1.354M	-$685.0K
Free Cash Flow	-$26.80M	-$21.02M	-$20.70M
YoY Change	29.45%	49.76%	-13.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001619856
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P10Y5M
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40631
	dei	Entity Registrant Name EntityRegistrantName	Caribou Biosciences, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-3728228
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2929 7th Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 105
	dei	Entity Address City Or Town EntityAddressCityOrTown	Berkeley
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94710
	dei	City Area Code CityAreaCode	510
	dei	Local Phone Number LocalPhoneNumber	982-6030
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	CRBU
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61001561	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82085000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	240420000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	211284000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	135412000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	397000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1153000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1899000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1488000	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	2699000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	5483000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8558000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7236000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	306922000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	391192000	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	7759000	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	7626000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	49221000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	37676000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8959000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4887000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24626000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1336000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	975000	usd
CY2022Q3	us-gaap	Assets Assets	398823000	usd
CY2021Q4	us-gaap	Assets Assets	442356000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1228000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3990000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14638000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13136000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	912000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q3	crbu	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	150000	usd
CY2021Q4	crbu	Deferred Revenue From Related Party DeferredRevenueFromRelatedParty	0	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	12036000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	8703000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	28814000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25829000	usd
CY2022Q3	crbu	Related Party Contract With Customer Liability Noncurrent RelatedPartyContractWithCustomerLiabilityNoncurrent	0	usd
CY2021Q4	crbu	Related Party Contract With Customer Liability Noncurrent RelatedPartyContractWithCustomerLiabilityNoncurrent	100000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15423000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	22032000	usd
CY2022Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2097000	usd
CY2022Q3	crbu	Success Payment Liability SuccessPaymentLiability	3039000	usd
CY2021Q4	crbu	Success Payment Liability SuccessPaymentLiability	4080000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26958000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Other Liabilities OtherLiabilities	0	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	17000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	475000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	476000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	74709000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	54531000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60986936	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60986936	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60263158	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60263158	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	496369000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	485748000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2035000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-135000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170226000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97794000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	324114000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	387825000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	398823000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	442356000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3303000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3977000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10159000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7039000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19991000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15833000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56494000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37144000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9849000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6760000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29486000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16469000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	29840000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	22593000	usd
	us-gaap	Operating Expenses OperatingExpenses	85980000	usd
	us-gaap	Operating Expenses OperatingExpenses	53613000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-26537000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18616000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-75821000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-46574000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	31000	usd
CY2021Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-73000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2022Q3	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	1607000	usd
CY2021Q3	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	2403000	usd
	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	-1041000	usd
	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	3584000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1584000	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1466000	usd
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	45000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2421000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	130000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-110000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2358000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3389000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1870000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-26647000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72432000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-48444000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-454000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1900000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27101000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74332000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48444000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.20
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.20
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60886921	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60886921	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45889646	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45889646	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60731520	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60731520	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22052944	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22052944	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	387825000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	361000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	629000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3024000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-19088000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-954000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	371797000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	363000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	593000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2918000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26697000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-492000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	347889000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	654000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2672000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-26647000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-454000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	324114000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-23437000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	564000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	343000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-13159000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-35689000	usd
CY2021Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1150000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	566000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-14311000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-47691000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	150150000	usd
CY2021Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	28600000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	321020000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	961000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	935000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	404401000	usd
	us-gaap	Profit Loss ProfitLoss	-72432000	usd
	us-gaap	Profit Loss ProfitLoss	-48444000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1116000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	711000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000	usd
	crbu	Non Cash Consideration For Licensing And Collaboration Revenue NonCashConsiderationForLicensingAndCollaborationRevenue	205000	usd
	crbu	Non Cash Consideration For Licensing And Collaboration Revenue NonCashConsiderationForLicensingAndCollaborationRevenue	0	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-73000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8615000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1871000	usd
	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	-1041000	usd
	crbu	Change In Fair Value Of Success Payments Liability ChangeInFairValueOfSuccessPaymentsLiability	3584000	usd
	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	300000	usd
	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	1000000	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	0	usd
	us-gaap	Extinguishment Of Debt Gain Loss Net Of Tax ExtinguishmentOfDebtGainLossNetOfTax	1578000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-106000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	crbu	Non Cash Lease Expense NonCashLeaseExpense	1622000	usd
	crbu	Non Cash Lease Expense NonCashLeaseExpense	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-756000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	428000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	411000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	525000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2783000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1673000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1613000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2759000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	361000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	151000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2568000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	848000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	909000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4855000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3277000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	30669000	usd
	crbu	Increase Decrease In Deferred Rent And Lease Incentive Liability IncreaseDecreaseInDeferredRentAndLeaseIncentiveLiability	0	usd
	crbu	Increase Decrease In Deferred Rent And Lease Incentive Liability IncreaseDecreaseInDeferredRentAndLeaseIncentiveLiability	909000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-279000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-15000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65922000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11130000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	163130000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	252552000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4697000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1436000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	300000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94419000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2436000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	321020000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	108827000	usd
	crbu	Proceeds From Exercise Of Stock Options And Purchases Of Common Stock Under Employee Stock Purchase Plan ProceedsFromExerciseOfStockOptionsAndPurchasesOfCommonStockUnderEmployeeStockPurchasePlan	2006000	usd
	crbu	Proceeds From Exercise Of Stock Options And Purchases Of Common Stock Under Employee Stock Purchase Plan ProceedsFromExerciseOfStockOptionsAndPurchasesOfCommonStockUnderEmployeeStockPurchasePlan	2091000	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	1150000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	119000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2006000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	432969000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-158335000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	419403000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	240466000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15953000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82131000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	435356000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82085000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	435310000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	46000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	46000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82131000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	435356000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	757000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	268000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	0	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1578000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	150150000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	26249000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business, Organization, and Liquidity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business and Organization</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caribou Biosciences, Inc. (the “Company” or “we”) is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing innovative, transformative therapies for patients with devastating diseases. CRISPR is an acronym for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lustered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">egularly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nterspaced </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hort </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alindromic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epeats. Our novel CRISPR platform, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RISPR </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ybrid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NA-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">DNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“chRDNA,” pronounced “chardonnay”), enables high genome-editing precision to develop cell therapies that are specifically engineered to target cancer and are armored for enhanced persistence. We are advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”)-T (“CAR-T”) and CAR-natural killer (“CAR-NK”) cell therapies for the treatment of patients with hematologic malignancies and solid tumors.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporated in October 2011 as a Delaware corporation and are headquartered in Berkeley, California. We have four wholly owned subsidiaries: Antler Holdco, LLC, incorporated in Delaware in April 2019; Microbe Holdco, LLC, incorporated in Delaware in June 2020; Arboreal Holdco, LLC, incorporated in Delaware in November 2020; and Biloba Holdco, LLC, incorporated in Delaware in April 2021. Our wholly owned subsidiaries hold interests in our equity investments and do not have operating activities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses and negative cash flows from operations since our inception and we had an accumulated deficit of $170.2 million as of September 30, 2022. During the nine months ended September 30, 2022, we incurred a net loss of $72.4 million and used $65.9 million of cash in operating activities. We expect to continue to incur substantial losses, and our ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of our product candidates and on our achievement of sufficient revenue to support our cost structure. We may never achieve profitability and, unless and until we do, we will need to continue to raise additional capital. Our management expects that existing cash, cash equivalents, and marketable securities of $342.6 million as of September 30, 2022, will be sufficient to fund our current operating plan for at least the next 12 months from the date of issuance of our condensed consolidated financial statements.</span></div>
	crbu	Number Of Subsidiaries NumberOfSubsidiaries	4	subsidiary
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65900000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	342600000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements; and the reported amounts of revenue, income, and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and assumptions, including those related to revenue recognition, common stock valuation, stock-based compensation expense, accrued expenses related to research and development activities, valuation of the Memorial Sloan Kettering Cancer Center (“MSKCC”) success payments liability, and income taxes. Our management bases its estimates on historical experience and on various other assumptions that they believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentration of credit risk consist of cash and cash equivalents, accounts receivable, contract assets, other receivables, and investments in marketable securities and equity securities. Substantially all of our cash and cash equivalents are deposited in accounts at two financial institutions, and account balances may at times exceed federally insured limits. We mitigate the risks by investing in high-grade instruments, limiting our exposure to one issuer, and we monitor the ongoing creditworthiness of the financial institutions and issuers. We believe these financial institutions to be of high credit quality.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensees that represent 10% or more of our revenue and accounts receivable and contract assets were as follows: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.087%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Accounts Receivable and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Contract Assets </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Nine Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">As of<br/>September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">As of<br/>December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Licensee A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">17.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">14.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">16.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">23.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">24.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Licensee B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">51.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">57.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">54.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">39.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">45.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Licensee C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> * </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">68.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">71.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">70.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">62.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">69.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">69.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">%</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Less than 10%</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor economic conditions to identify facts or circumstances that may indicate if any of our accounts receivable are not collectible or if the contract assets should be impaired. No allowance for doubtful accounts or contract asset impairment was recorded as of September 30, 2022 or December 31, 2021.</span></div>
CY2022Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	0	usd
CY2022Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22818000	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13819000	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23941000	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	800000	usd
CY2022Q1	crbu	Reclassification Adjustment On Operating Lease Liability Current ReclassificationAdjustmentOnOperatingLeaseLiabilityCurrent	100000	usd
CY2022Q3	crbu	Cash Cash Equivalents And Available For Sale Debt Securities Amortized Cost CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost	344626000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2037000	usd
CY2022Q3	crbu	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	342590000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82085000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	211284000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	49221000	usd
CY2022Q3	crbu	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	342590000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	413643000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	141000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	413508000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	240420000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	135412000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	37676000	usd
CY2021Q4	crbu	Cash Cash Equivalents And Available For Sale Debt Securities CashCashEquivalentsAndAvailableForSaleDebtSecurities	413508000	usd
	crbu	Accounts Receivable Additions AccountsReceivableAdditions	6271000	usd
	crbu	Accounts Receivable Deductions AccountsReceivableDeductions	7027000	usd
CY2021Q3	crbu	Increase Decrease In Fair Value Of Success Payments Liability IncreaseDecreaseInFairValueOfSuccessPaymentsLiability	2400000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3303000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3977000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10159000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7039000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1153000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	397000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1488000	usd
	crbu	Contract With Customer Assets Additions ContractWithCustomerAssetsAdditions	5486000	usd
	crbu	Contract With Customer Assets Deductions ContractWithCustomerAssetsDeductions	5075000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1899000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30735000	usd
	crbu	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	3514000	usd
	crbu	Contract With Customer Liability Deductions ContractWithCustomerLiabilityDeductions	6791000	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	27458000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3400000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	100000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	43400000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	12000000	usd
CY2022Q3	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q3	crbu	Patent Cost Reimbursements PatentCostReimbursements	2197000	usd
CY2021Q4	crbu	Patent Cost Reimbursements PatentCostReimbursements	4702000	usd
CY2022Q3	us-gaap	Marketable Securities MarketableSecurities	499000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	226000	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	555000	usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables	2699000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	5483000	usd
CY2022Q3	crbu	Prepaid Contract Manufacturing And Clinical Costs PrepaidContractManufacturingAndClinicalCosts	4789000	usd
CY2021Q4	crbu	Prepaid Contract Manufacturing And Clinical Costs PrepaidContractManufacturingAndClinicalCosts	2714000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	2228000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1897000	usd
CY2022Q3	us-gaap	Prepaid Taxes PrepaidTaxes	438000	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1486000	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	0	usd
CY2021Q4	us-gaap	Prepaid Rent PrepaidRent	468000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1103000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	671000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8558000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7236000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14140000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8964000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5181000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4077000	usd
CY2022Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8959000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4887000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	400000	usd
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	300000	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	1100000	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Reclassifications From Property Plant And Equipment1 AccumulatedDepreciationDepletionAndAmortizationReclassificationsFromPropertyPlantAndEquipment1	700000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4631000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4225000	usd
CY2022Q3	crbu	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	5717000	usd
CY2021Q4	crbu	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	4065000	usd
CY2022Q3	crbu	Accrued Patent Expenses Current AccruedPatentExpensesCurrent	1877000	usd
CY2021Q4	crbu	Accrued Patent Expenses Current AccruedPatentExpensesCurrent	3213000	usd
CY2022Q3	crbu	Accrued Sublicensing Fees AccruedSublicensingFees	528000	usd
CY2021Q4	crbu	Accrued Sublicensing Fees AccruedSublicensingFees	586000	usd
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	259000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1885000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	788000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14638000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	13136000	usd
CY2018Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1100000	usd
CY2018Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0304
CY2018Q4	crbu	Common Stock Shares Held Collateral For Debt CommonStockSharesHeldCollateralForDebt	409795	shares
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1200000	usd
CY2021Q1	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P10Y
CY2021Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2022Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	10000	sqft
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	400000	usd
CY2022Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1822000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5443000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	83000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	1822000	usd
	us-gaap	Lease Cost LeaseCost	5526000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	600000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1600000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2454000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1129
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	681000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3197000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4353000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4475000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5720000	usd
CY2022Q3	crbu	Lessee Operating Lease Liability Payments Due Year Four And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter	28037000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46463000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18593000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	27870000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	912000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26958000	usd
	crbu	Expected Incentive Offset In First Year ExpectedIncentiveOffsetInFirstYear	100000	usd
	crbu	Expected Incentive Offset In Second Year ExpectedIncentiveOffsetInSecondYear	1500000	usd
	crbu	Expected Incentive Offset In Third Year ExpectedIncentiveOffsetInThirdYear	200000	usd
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	0	usd
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13909940	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11017930	shares
CY2022Q3	crbu	Sale Of Stock Authorized Amount Under Shelf Registration SaleOfStockAuthorizedAmountUnderShelfRegistration	400000000	usd
CY2021Q3	crbu	Common Stock Outstanding Percentage CommonStockOutstandingPercentage	0.05
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6757591	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.57
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	50085000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1206750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.88
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	654665	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	659784	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.74
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6649892	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24431000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2207115	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.13
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	12416000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6649892	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	24431000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.742
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.748
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.011
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	29200000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1871000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	100000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2673000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	935000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8615000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1871000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2673000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	935000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8615000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-26647000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-20974000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-72432000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-48444000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60886921	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60886921	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45889646	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45889646	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60731520	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60731520	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22052944	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22052944	shares
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.20
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6958770	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4984756	shares

Files In Submission

Name	View Source	Status
crbu-20220930_lab.xml	Edgar Link	unprocessable
crbu-20220930_cal.xml	Edgar Link	unprocessable
0001619856-22-000022-index-headers.html	Edgar Link	pending
0001619856-22-000022-index.html	Edgar Link	pending
0001619856-22-000022.txt	Edgar Link	pending
0001619856-22-000022-xbrl.zip	Edgar Link	pending
crbu-20220930.htm	Edgar Link	pending
crbu-20220930.xsd	Edgar Link	pending
crbu-20220930xexx311.htm	Edgar Link	pending
crbu-20220930xexx312.htm	Edgar Link	pending
crbu-20220930xexx321.htm	Edgar Link	pending
crbu-20220930xexx322.htm	Edgar Link	pending
exhibit101-rsuagreement.htm	Edgar Link	pending
exhibit102-psuagreement.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
crbu-20220930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crbu-20220930_pre.xml	Edgar Link	unprocessable
crbu-20220930_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRBU
Caribou Biosciences Inc Stock $crbu

2022 Q4 Form 10-Q Financial Statement

#000161985622000022 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRBU Caribou Biosciences Inc Stock $crbu

2022 Q4 Form 10-Q Financial Statement

#000161985622000022 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRBU
Caribou Biosciences Inc Stock $crbu